Trial Profile
The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by previous alpha-1-blockades.A comparison of Naftopidil or Silodosin.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Naftopidil (Primary) ; Silodosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Adverse reactions; Therapeutic Use
- 13 May 2016 New trial record